Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paromomycin is an aminoglycoside antibiotic produced by various Streptomyces species. It is primarily used to treat acute and chronic intestinal amebiasis, as well as other intestinal parasitic infections such as giardiasis, cryptosporidiosis, and tapeworm infections. It is also used as adjunctive therapy in the management of hepatic coma due to its ability to reduce ammonia-producing gut bacteria. The drug acts by binding to the 16S rRNA of the bacterial ribosome, inhibiting protein synthesis and leading to cell death in susceptible organisms. It has poor oral absorption, so its effects are largely confined to the gastrointestinal tract[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paromomycin.